MIRACL

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes - Journal of the American Medical Association - 2001

Brief Summary:

Early initiation of atorvastatin post-UA/NSTEMI reduced the combined endpoint of death, nonfatal MI, cardiac arrest, and ACS requiring hospitalization at 16 weeks, when compared to placebo.

Reference:
http://www.ncbi.nlm.nih.gov/pubmed/11277825